Platelet Count in Patients with Mild Disease at Admission is Associated with Progression to Severe Hantavirus Cardiopulmonary Syndrome.
Hantavirus cardiopulmonary syndrome
Hantavirus pulmonary syndrome
thrombocytopenia
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
30 07 2019
30 07 2019
Historique:
received:
01
06
2019
revised:
18
07
2019
accepted:
19
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
26
9
2020
Statut:
epublish
Résumé
Hantavirus cardiopulmonary syndrome (HCPS) has a mortality up to 35-40% and its treatment is mainly supportive. A variable to predict progression from mild to severe disease is unavailable. This study was performed in patients with documented infection by Andes orthohantavirus, and the aim was to find a simple variable to predict progression to moderate/severe HCPS in patients with mild disease at admission. We performed a retrospective analysis of 175 patients between 2001 and 2018. Patients were categorized into mild, moderate, and severe disease according to organ failure and advanced support need at hospital admission (e.g., mechanical ventilation, vasopressors). Progression to moderate/severe disease was defined accordingly. Clinical and laboratory variables associated with progression were explored. Forty patients with mild disease were identified; 14 of them progressed to moderate/severe disease. Only platelet count was different between those who progressed versus those that did not (37 (34-58) vs. 83 (64-177) K/mm In patients with mild disease at presentation, platelet count could help to define priority of evacuation to tertiary care centers.
Sections du résumé
BACKGROUND
Hantavirus cardiopulmonary syndrome (HCPS) has a mortality up to 35-40% and its treatment is mainly supportive. A variable to predict progression from mild to severe disease is unavailable. This study was performed in patients with documented infection by Andes orthohantavirus, and the aim was to find a simple variable to predict progression to moderate/severe HCPS in patients with mild disease at admission.
METHODS
We performed a retrospective analysis of 175 patients between 2001 and 2018. Patients were categorized into mild, moderate, and severe disease according to organ failure and advanced support need at hospital admission (e.g., mechanical ventilation, vasopressors). Progression to moderate/severe disease was defined accordingly. Clinical and laboratory variables associated with progression were explored.
RESULTS
Forty patients with mild disease were identified; 14 of them progressed to moderate/severe disease. Only platelet count was different between those who progressed versus those that did not (37 (34-58) vs. 83 (64-177) K/mm
CONCLUSIONS
In patients with mild disease at presentation, platelet count could help to define priority of evacuation to tertiary care centers.
Identifiants
pubmed: 31366116
pii: v11080693
doi: 10.3390/v11080693
pmc: PMC6724000
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : 5U19AI045452
Pays : United States
Références
Microbes Infect. 1999 Dec;1(14):1229-37
pubmed: 10580279
Am J Clin Pathol. 2001 Nov;116(5):665-72
pubmed: 11710682
Emerg Infect Dis. 2003 Nov;9(11):1438-43
pubmed: 14718088
Curr Opin Infect Dis. 2006 Oct;19(5):437-42
pubmed: 16940866
Emerg Infect Dis. 2006 Aug;12(8):1271-3
pubmed: 16965713
J Infect Dis. 2007 Jun 1;195(11):1563-71
pubmed: 17471425
J Virol. 2009 Mar;83(6):2446-59
pubmed: 19116256
Thromb Haemost. 2009 Dec;102(6):1030-41
pubmed: 19967132
J Virol. 2010 May;84(9):4832-9
pubmed: 20181715
Emerg Infect Dis. 2011 Jul;17(7):1195-201
pubmed: 21762572
Eur J Cardiothorac Surg. 2011 Dec;40(6):1334-40
pubmed: 21900022
PLoS One. 2013;8(1):e53236
pubmed: 23301047
Clin Infect Dis. 2013 Oct;57(7):943-51
pubmed: 23784924
Emerg Infect Dis. 2014 Mar;20(3):386-93
pubmed: 24565589
Swiss Med Wkly. 2014 Mar 20;144:w13937
pubmed: 24652684
Emerg Infect Dis. 2014 Oct;20(10):1629-36
pubmed: 25272189
Antivir Ther. 2015;20(4):377-86
pubmed: 25316807
J Infect Dis. 2015 Oct 1;212(7):1061-9
pubmed: 25762786
Diagn Microbiol Infect Dis. 2016 Jan;84(1):36-39
pubmed: 26508102
Infect Dis (Lond). 2016 Sep;48(9):682-7
pubmed: 27299174
Rev Chilena Infectol. 2016 Jun;33(3):275-81
pubmed: 27598275
Nucleic Acids Res. 2018 Jan 4;46(D1):D708-D717
pubmed: 29040670
Dis Markers. 2018 Jun 19;2018:9701619
pubmed: 30018676
N Engl J Med. 1994 Apr 7;330(14):949-55
pubmed: 8121458
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Virology. 1998 Feb 15;241(2):323-30
pubmed: 9499807
Dis Mon. 1998 Mar;44(3):85-138
pubmed: 9520902
J Hosp Infect. 1998 Dec;40(4):281-5
pubmed: 9868619